A bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines.Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “OLYMVAX” or “the Company”) is a bio-pharmaceutical enterprise specializing in the R&D, production and sales of human vaccines. The Company was founded in 2009 with a registered capital of RMB 405,265,000 and was successfully listed on the SSE Science and Technology Innovation Board (Stock Code: 688319) on June 8, 2021. Since its establishment, the Company has been committed to providing consumers at home and abroad with safe, effective and high-quality human vaccine products, including the upgrade products of traditional vaccines developed to improve the quality of life of the people with broad market demand, and the innovative vaccine products with great future market potential, which are not yet met or urgently needed for disease control and prevention. Currently, it has been granted 80 Chinese invention patents, 3 US patents and 1 European patent.
Adhering to the business philosophy of “strengthening process management, focusing on continuous improvement, and pursuing the highest quality”, the Company aims to become an "internationally renowned and domestically leading" vaccine supplier. In terms of construction and management of pharmaceutical production workshops, the Company has built and managed them in accordance with the 2010 Version of Chinese GMP and with reference to the standards of developed countries in Europe and America, laying a solid foundation for its products to enter the international market. In the aspect of product development, the Company has established a well-developed research and development system, and two subsidiaries, Chongqing Yuanlun Biotechnology Co., Ltd. and Chengdu XENOMIX Biotechnology Co., Ltd., jointly implementing a dual-wheel drive strategy of leveraging the strengths of innovative vaccine development and traditional vaccine upgrading and a R&D strategy of laying equal stress on independent development and joint development. At present, the Company has 3 vaccine products launched and formed a product pipeline of “multi-product reserve, orderly stepping and key breakthrough”.
2009year
Established in77000㎡
Planned floor area440
Existing employees3
Marketed products
No matter what twists and turns and no matter what difficulties and obstacles are in the way of an enterprise’s birth and development, as long as there is stable faith and a consolidated goal, the enterprise will grow better and better and finally achieve success.
Since its founding, Olymvax always keeps to its original development orientation, taking scientific research and its related achievements transformation as its duty; taking “products that benefit mankind” and “becoming the leading enterprise in the industry” as its business goal. Olymvax has formed a development process supported by an outstanding and independent R&D ability, solid accumulation of technological innovation, farsighted product configuration and strict quality assurance system.
In the coming future, shouldering the holy mission of providing human beings with vaccines that are safer, better and more effective; upholding the principles of “honesty, dedication, innovation and transcendence”; adopting the world’s leading managerial technique, Olymvax will never cease to innovate and excell; Olymvax is comitted to becoming an internationally well-known, domestically leading supplier of vaccines.
Olymvax strives to provide a strong development platform for each employee, to give a stable return on investment to each investor, to make professional contributions to social progress and technical development. I believe that with the help and support of all Olymvax staff and cooperative partners, our goal will finally be achieved.
Olymvax management team consists of professional personnel who have years of experience in bio-pharmaceutical business and those who have backgrounds of security, finance, marketing and overseas work or study experience. They have an average work experience of over 20 years. The management team has both smart responsibility assignment and strong team work spirit. Thus, the efficient running and rapid development of Olymvax’s businesses can be ensured.
November
The company was selected into the list of "2025 Sichuan Top 100 Private Enterprises in R&D Investment".
October
The Quadrivalent Influenza Vaccine (Split Virion), Inactivated (MDCK Cell) has entered Phase III clinical trial; The company was successfully selected into the "Sichuan Top 100 R&D Enterprises" list;
September
The Haemophilus Influenzae Type b Conjugate Vaccine was honored to be selected as the Chengdu Industrial Boutique;
February
The "GAS Project Cooperation" (GAS Vaccine Contract Manufacturing) project between the company and Griffith University was launched;The Phase I clinical trials of Trivalent and Quadrivalent Influenza Vaccine (Split Virion), Inactivated (MDCK Cell) were launched;
January
The Adsorbed Tetanus Vaccine was rated as the Benchmark of the "Three Products" Initiative in the consumer goods industry of Sichuan Province; The company was successfully selected into the 2024 Sichuan Top 100 New Economy Enterprises List;
December
The company has been recognized as the Sichuan Provincial Growth-oriented Headquarter Enterprise; The company was honored with the Second Prize of 2023 Productivity Promotion (Innovation Development); The company was selected into the Top 50 Sichuan Pharmaceutical Enterprises for the first time;
November
The company was selected as the Typical Practice Case of the Board of Directors of Listed Companies (2024) by the China Association for Public Companies;Research Institute（Chongqing）was completed and inaugurated in Shapingba District, Chongqing;Research Institute（Chongqing） was successfully approved for the 2024 Chongqing Major Special Project for Technological Innovation and Application Development;
October
The company was recognized as the Sichuan Provincial Model Enterprise for Technological Innovation; The Adsorbed Tetanus Vaccine was honored to be selected as the Chengdu Industrial Boutique; The company obtained the Drug Clinical Trial Approval of Trivalent Influenza Vaccine (Split Virion), Inactivated (MDCK Cell);
August
The company was included in the SSE STAR Market 200 Index and the SSE STAR Market Innovative Drug Index;The company was honored with First Prize of Chongqing Municipal Science and Technology Invention Award;
July
The company was listed on the "China Brand Value List 2024 of China Brand Building Promotion Association";
June
The original Class 1.1 new drug, Oral Recombinant Helicobacter Pylori Vaccine was granted Phase I Clinical Trial Approval in Australia;
May
The company was awarded the title of 2024 "Golden Panda Future Star" Enterprise;The company obtained the Drug Clinical Trial Approval of Quadrivalent Influenza Vaccines (Split Virion), Inactivated (MDCK Cell);
March
The company was awarded the China Industry-University-Research Cooperation Innovation Award;
February
The company was selected into the "2023 Sichuan Top 100 New Economy Enterprises List”;
December
The company was rated as the Chengdu Olymvax Biopharmaceuticals Human Vaccine Pilot Test Platform;The company was selected into the “2023 Chengdu Municipal-Level Contract Abiding and Trustworthy Enterprise List”;
November
The company was rated as the Sichuan Provincial Intellectual Property Strong Enterprise;The company was rated as the Biovaccine Pilot Test Platform of the High-tech Zone;
October
The company was approved to establish the Sichuan Provincial Postdoctoral Innovation Practice Base;The project of the original Class 1.1 new drug—Recombinant Four-Antigen Pseudomonas Aeruginosa Vaccine was launched;
June
The company was rated as the 2023 Sichuan Provincial Industrial Quality Benchmark;The company was honored with the Second Prize of Sichuan Provincial Patent Award;
May
The company was approved as the Sichuan Provincial Engineering Technology Research Center for Human Vaccines;The project of Recombinant Acinetobacter Baumannii Subunit Vaccine was launched;
April
The company was approved to establish the Sichuan Provincial Foreign-Related Intellectual Property Work Guidance Station;
March
The company was included in the list of eligible securities for Shanghai Stock Connect;
January
The company was included in the “2022 Sichuan Top 100 New Economy Enterprises List”; The company was included in the 2022 "Innovation China" Forerunner Technology List;
December
Research Institute（Chengdu） was completed and launched in Chengdu Tianfu International Bio-town;The company was awarded the "2021 Annual Listed Company Golden Bull Innovation and Technology Award";
November
The company was successfully selected into the SSE STAR Innovation Growth Index (Index Code: 000690);
October
The company was awarded the title of "2022 National Intellectual Property Advantageous Enterprise";
July
The project of Quadrivalent Influenza Vaccines (Split Virion), Inactivated (MDCK Cell) was launched;
June
The PhaseⅢclinical trial of the original Class 1.1 new drug—Recombinant Staphylococcus Aureus Vaccine was officially launched;
April
The company was successfully selected into the SSE STAR Market Biomedicine Index (Index Code: 000683);
October
The company was recognized as the "2021 Chengdu Key Enterprise & Leading Listed Enterprise"; The company was recognized as the "Sichuan Provincial Enterprise Technology Center";
September
The company was honored as the "Credible Enterprise" of Sichuan Province;
June
The company was listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (Stock Code: 688319); The company was awarded the title of "Chengdu Demonstration Base for Talent and Intelligence Introduction";
September
The company obtained the Drug Registration Approval Certificate of Group A and Group C Meningococcal Conjugate Vaccine;
July
The company was awarded the title of Municipal Engineering Technology Research Center;
July
The company was recognized as Chengdu Enterprise Technology Center;
June
The Phase Ⅱ clinical trial of the original Class 1.1 new drug—Recombinant Staphylococcus Aureus Vaccine was officially launched.
February
The company obtained the Intellectual Property Management System Certification Certificate for the first time;
December
The company successfully passed the Work Safety Standardization Certification for the first time.
May
The company obtained the Drug Registration Approval Certificate of Haemophilus Influenzae Type b Conjugate Vaccine;
March
The company was awarded the "2016 Intelligent Manufacturing Demonstration Enterprise" in the High-tech Zone;
January
The company obtained the Drug Clinical Trial Approval of Group A and Group C Meningococcal - Haemophilus Influenzae Type b (Conjugate) Combined Vaccine;
October
The company obtained the Drug Registration Approval Certificate of the Adsorbed Tetanus Vaccine;
July
The cooperative research and development of the original Class 1.1 new drug Group A Streptococcus Vaccine was officially launched;
September
The company was listed on the National Equities Exchange and Quotations (NEEQ), with the securities short name "Olymvax" (securities code: 833577);
August
The company obtained the Drug Clinical Trial Approval of the Group A and Group C Meningococcal Conjugate Vaccine;
June
The company acquired Chongqing Yuanlun Biotechnology Co., Ltd.; The company obtained the Drug Clinical Trial Approval of the original Class 1.1 new drug - Recombinant Staphylococcus Aureus Vaccine;
October
The company obtained the High-Tech Enterprise Certificate for the first time;
April
The company obtained the Drug Clinical Trial Approval of Haemophilus Influenzae Type b Conjugate Vaccine;
October
The Phase I project of the company's vaccine R&D and production base (with a floor area of 39,000 square meters) was completed and put into operation; The company obtained the Clinical Trial Approval of Adsorbed Tetanus Vaccine;
February
The company's registered capital was increased to 100 million yuan;
July
The company obtained the Drug Manufacturing License;
May
The company's vaccine R&D laboratory was completed and put into use;
December
Chengdu Olymvax Biopharmaceuticals Inc. was established with a registered capital of 50 million yuan;
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
On December 11, 2025, Mr. Matthew Fosbery, Deputy Commercial Consul of Australia in Chengdu and Trade & Investment Commissioner of Austrade, and Ms. Wang Ming, Commercial Officer of Austrade, visited Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, stock code: 688319) for inspection and exchanges, and had in-
The Second Badminton Competition of the OLYMVAX Cup - “Hold Badminton Flying, Keep You and Me Moving”
2019-04-10
“Never Fade Charms, Keep Original Aspiration” - 2018 Appreciation and Spring Festival Meeting
2019-04-10
